Consumer Non-Durables
Japan Tobacco Inc.
In the news
- Kirin activist admits 'ambitious' target for crunch investor meeting Mar 12, 2020
- Activist fund pushes Kirin to accept two outside directors Feb 19, 2020
- World bets on existing drugs to combat coronavirus Feb 4, 2020
- Foreigners flee region as Iran strikes back at US Jan 8, 2020
- Japan Post scandal shows external directors unable to do their jobs Jan 7, 2020 See more articles on Japan Tobacco Inc.
Business Summary
Japan Tobacco, Inc. engages in the manufacture and sale of tobacco, pharmaceutical and processed food products. It operates through the following divisions: Japanese Domestic Tobacco, International Tobacco, Pharmaceutical, and Processed Food. The Japanese Domestic segment deals with the production and sale of tobacco products in domestic areas. The International Tobacco segment manufactures and markets tobacco products worldwide. The Pharmaceutical segment develops, manufactures, and sells prescription drugs. The Processed Food segment offers processed food, bakery products and seasonings. The company was founded on April 1, 1985 and is headquartered in Tokyo, Japan.
Financial Highlights
| Dec 2019 | JPY | USD |
| Revenue | 2,175.62B | 19,957.89M |
| Gross Profit | 1,127.23B | 10,340.56M |
| Operating income | 452,618M | 4,152.04M |
| Income before tax | 465,232M | 4,267.75M |
| Net income | 348,190M | 3,194.08M |
| EBITDA | 635,937M | 5,833.70M |
| Diluted EPS | 195.87 | 1.79 |
| Dividends Per Share | 154 | 1.41 |
| Total Assets | 5,553.07B | 51,097.96M |
| Total liabilities | 2,809.46B | 25,851.95M |
| Total equity | 2,662.69B | 24,501.45M |
| Operating cash flow | 540,410M | 4,957.39M |
| Currency in JPY | Currency in USD |
Historical Data
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | |
| Revenue | 2,252.88B | 2,143.28B | 2,139.65B | 2,215.96B | 2,175.62B |
| Gross Profit | 1,267.68B | 1,192.41B | 1,215.36B | 1,195.57B | 1,127.23B |
| Operating income | 591,831M | 535,001M | 526,027M | 532,832M | 452,618M |
| Income before tax | 558,732M | 571,748M | 538,532M | 531,486M | 465,232M |
| Net income | 398,454M | 421,695M | 392,409M | 385,676M | 348,190M |
| EBITDA | 730,032M | 675,146M | 670,864M | 690,929M | 635,937M |
| Diluted EPS | 270.37 | 235.33 | 218.97 | 215.20 | 195.87 |
| Dividends Per Share | 118 | 130 | 140 | 150 | 154 |
| Total Assets | 4,558.23B | 4,744.37B | 5,221.48B | 5,461.40B | 5,553.07B |
| Total liabilities | 2,036.71B | 2,216.33B | 2,379.45B | 2,760.95B | 2,809.46B |
| Total equity | 2,451.59B | 2,456.09B | 2,761.68B | 2,630.59B | 2,662.69B |
| Operating cash flow | 468,432M | 376,549M | 419,212M | 461,389M | 540,410M |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | |
| Revenue | 18,608.90M | 19,724.90M | 19,081.27M | 20,064.33M | 19,957.89M |
| Gross Profit | 10,471.12M | 10,973.92M | 10,838.55M | 10,825.28M | 10,340.56M |
| Operating income | 4,888.54M | 4,923.67M | 4,691.07M | 4,824.50M | 4,152.04M |
| Income before tax | 4,615.14M | 5,261.86M | 4,802.58M | 4,812.31M | 4,267.75M |
| Net income | 3,291.24M | 3,880.90M | 3,499.47M | 3,492.08M | 3,194.08M |
| EBITDA | 6,030.09M | 6,213.44M | 5,982.71M | 6,255.98M | 5,833.70M |
| Diluted EPS | 2.23 | 2.16 | 1.95 | 1.94 | 1.79 |
| Dividends Per Share | 0.97 | 1.19 | 1.24 | 1.35 | 1.41 |
| Total Assets | 37,892.14M | 40,677.10M | 46,351.38M | 49,778.06M | 51,097.96M |
| Total liabilities | 16,930.97M | 19,002.29M | 21,122.55M | 25,164.79M | 25,851.95M |
| Total equity | 20,379.85M | 21,057.92M | 24,515.64M | 23,976.61M | 24,501.45M |
| Operating cash flow | 3,869.26M | 3,465.42M | 3,738.50M | 4,177.62M | 4,957.39M |
Valuation Measures
| Dec 2019 | |
| PER | 12.41 |
| ROA | 6.32% |
| ROE | 13.15% |
| Operating margin | 20.80% |
| Profit margin | 16.00% |
Key executives
- President, CEO & Representative Director: Masamichi Terabatake
- CFO, Representative Director & Executive VP: Naohiro Minami
- Executive Officer, Head-Research & Development: Hiroyuki Miki
- Director, Head-Compliance & General Affairs: Kazuhito Yamashita
- Executive Officer & Head-Digitalization: Takehisa Shibayama
Shareholders
- Government of Japan (33.3%)
- Japan Tobacco Inc. (11.2%)
- Nomura Asset Management Co., Ltd. (2.2%)
- The Vanguard Group, Inc. (1.8%)
- Mizuho Bank Pension Fund (1.1%)
- Daiwa Asset Management Co. Ltd. (1.0%)
- Nikko Asset Management Co., Ltd. (1.0%)
- BlackRock Fund Advisors (0.9%)
- Massachusetts Financial Services Co. (0.7%)
- Capital Research & Management Co. (Global Investors) (0.6%)
Contact Details
- Website:http://www.jti.co.jp
- Address: 2-2-1 Toranomon, Minato-Ku, Tokyo, 105-8422, Japan
- Phone: +81.3.3582.3111
Related Companies
- Japan Tobacco Restricted Stock Compensation Plan
- Tokai Plant Service Co., Ltd.
- JTI (RMS) Ltd.
- Emerging Products Holding BV
- JTI Business Services (Asia) Sdn. Bhd.
- JTI Processadora de Tabaco do Brasil Ltda.
- United Dhaka Tobacco Co. Ltd.
- PT Karyadibya Mahardhika
- PT Surya Mustika Nusantara
- Fluxo Brasil Distribuidora de Produtos SA
- Reynolds American, Inc. /Natural American Cigarettes 9/
- JTI Tutun Urunleri Sanayi AS
- JT International Group Holding BV
- Shanghai JS Foods Co. Ltd.
- Japan Tobacco (Hong Kong) Ltd.
- Logic Technology Development LLC
- JT International Co. Ukraine CJSC
- JTI Tutun Urunleri Pazarlama AS
- JT (UK) Ltd.
- Zandera Ltd.
- Al Nakhla Tobacco Free Zone SAE
- Batata SA /Subsdiaries (2)/
- Al Nakhla Tobacco Co. SAE
- JT International (Asia Pacific) Ltd.
- JT International (Philippines), Inc.
- Haggar Cigarette & Tobacco Factory Ltd. (South Sudan)
- Haggar Holding Co. /Sudan Cigarette & Tobacco Business (2)/
- National Tobacco Enterprise (Ethiopia) Share Co.
- JT International India Pvt Ltd.
- JT America, Inc.
Competitors
- British American Tobacco p.l.c.
- Imperial Brands PLC
- Philip Morris International Inc.
- Swedish Match AB
- Ajinomoto Co., Inc.
- Maruha Nichiro Corp.
- Nichirei Corporation
- Nippon Suisan Kaisha, Ltd.
- LT Group, Inc.
- Akebia Therapeutics, Inc.
- Eastern Company
- Electronic Cigarettes International Group Ltd.
- Reata Pharmaceuticals, Inc. Class A
- FibroGen, Inc.
- Charlie's Holdings Inc
- 22nd Century Group, Inc.
- Arcutis Biotherapeutics Inc
- NGM Biopharmaceuticals, Inc.
- Schweitzer-Mauduit International, Inc.
- JW Pharmaceutical Corporation
- Immunic, Inc.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 7 Aug, 2020